Financial Survey: Vericel (NASDAQ:VCEL) and Lucid Diagnostics (NASDAQ:LUCD)

Vericel (NASDAQ:VCEL) and Lucid Diagnostics (NASDAQ:LUCD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Profitability

This table compares Vericel and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	N/A	N/A	N/A
Lucid Diagnostics	N/A	N/A	N/A

Valuation and Earnings

This table compares Vericel and Lucid Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30 million	7.23	$24.07 million	$0.47	92.06
Lucid Diagnostics	$5.45 million	16.35	-$95.52 million	($0.47)	-0.93

Vericel has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vericel has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Vericel and Lucid Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	2	4	0	2.67
Lucid Diagnostics	1	0	4	0	2.60

Vericel currently has a consensus price target of $57.20, indicating a potential upside of 32.19%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 855.83%. Given Lucid Diagnostics’ higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Vericel.

Summary

Vericel beats Lucid Diagnostics on 6 of the 10 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.